Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

528205 Plasminogen Activator Inhibitor-1, Human, Recombinant - Calbiochem

The Plasminogen Activator Inhibitor-1, Human, Recombinant controls the biological activity of Plasminogen Activator. This small molecule/inhibitor is primarily used for Protease Inhibitors applications.

Plasminogen Activator Inhibitor-1, Human, Recombinant - Calbiochem MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

Synonyms: PAI-1

Primary Target: Tissue plasminogen activator (tPA) and urokinase (uPA)
528205
Purchase on Sigma-Aldrich

Przegląd

Replacement Information

Products

Numer katalogowyOpakowanie Ilość/opak.
528205-50UG Ampulka plastikowa 50 μg
Description
OverviewPAI-1 is the primary inhibitor of both tissue plasminogen activator (tPA) and urokinase (uPA). PAI-1 can exist either in an active inhibitory conformation or in an inactive or latent conformation. This highly purified preparation has not been exposed to denaturing conditions and has been chromatographically purified of latent material. PAI-1 is a marker for acute myocardial infarction and several thrombolytic disorders. Protects platelets against the inhibitory effects of plasma. Reported to be an important prognostic factor in breast cancer patients. PAI-1 is highly stable when stored at or below pH 6.6.
Catalogue Number528205
Brand Family Calbiochem®
SynonymsPAI-1
References
ReferencesVaughan, D.E., et al. 1995. J. Clin. Invest. 95, 995.
Dimitri, G., et al. 1993. Boll. Chim. Farmaceutico 132, 272.
Janicke, F., et al. 1993. Breast Cancer Res. Treatment 24, 195.
Klasser, K.J., et al. 1993. Coron. Artery Dis. 4, 713.
Robbie, L.A., et al. 1993. Thromb. Hemost. 70, 307.
Lawrence, D., et al. 1989. Eur. J. Biochem. 186, 523.
Collen, D. and Lijnen, H.R. 1987. In The Molecular Basis of Blood Diseases (Stamatoyannopoulus, G., et al. Eds.) W.B. Saunders
Ginsberg, D., et al. 1986. J. Clin. Invest. 78, 1673.
Vassalli, J.D., et al. 1985. J. Cell Biol. 100, 86.
Product Information
ATP CompetitiveN
FormLiquid
FormulationIn 150 mM NaCl, 50 mM sodium phosphate buffer, 1 mM EDTA, pH 6.6.
ReversibleN
Quality LevelMQ100
Applications
Biological Information
Primary TargetTissue plasminogen activator (tPA) and urokinase (uPA)
Purity≥95% by SDS-PAGE
Physicochemical Information
Cell permeableN
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Dry Ice Only
Toxicity Standard Handling
Storage ≤ -70°C
Avoid freeze/thaw Avoid freeze/thaw
Do not freeze Ok to freeze
Special InstructionsFollowing initial thaw, aliquot and freeze (-70°C).
Packaging Information
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Numer katalogowy GTIN
528205-50UG 04055977196481

Documentation

Plasminogen Activator Inhibitor-1, Human, Recombinant - Calbiochem MSDS

Title

Safety Data Sheet (SDS) 

Plasminogen Activator Inhibitor-1, Human, Recombinant - Calbiochem Certificates of Analysis

TitleLot Number
528205

References

Przegląd literatury
Vaughan, D.E., et al. 1995. J. Clin. Invest. 95, 995.
Dimitri, G., et al. 1993. Boll. Chim. Farmaceutico 132, 272.
Janicke, F., et al. 1993. Breast Cancer Res. Treatment 24, 195.
Klasser, K.J., et al. 1993. Coron. Artery Dis. 4, 713.
Robbie, L.A., et al. 1993. Thromb. Hemost. 70, 307.
Lawrence, D., et al. 1989. Eur. J. Biochem. 186, 523.
Collen, D. and Lijnen, H.R. 1987. In The Molecular Basis of Blood Diseases (Stamatoyannopoulus, G., et al. Eds.) W.B. Saunders
Ginsberg, D., et al. 1986. J. Clin. Invest. 78, 1673.
Vassalli, J.D., et al. 1985. J. Cell Biol. 100, 86.
Data Sheet

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision24-August-2023 JSW
SynonymsPAI-1
DescriptionPrimary inhibitor of both tissue plasminogen activator (tPA) and urokinase (uPA). PAI-1 is synthesized by vascular epithelium and hepatocytes. Used as a marker for acute myocardial infarction and in the diagnosis of several thrombolytic disorders. Protects platelets against the inhibitory effects of plasma. Shown to have a role complimentary to that of α2-anti-plasmin. Elevated levels are found in subjects with accelerated coronary artery disease. PP1 activity may limit the extent of metastasis, since uPA activity is a major contributory factor promoting dissolution of tumor matrix and basement membrane. May serve as an independent and strong prognosticator in breast cancer patients. Patients having elevated levels of PAI-1 in their primary tumors are more prone to relapse. Can exist either in an active inhibitory conformation or in an inactive or latent conformation. This highly purified preparation has not been exposed to denaturing conditions and has been chromatographically purified free of the inactive material.
FormLiquid
FormulationIn 150 mM NaCl, 50 mM sodium phosphate buffer, 1 mM EDTA, pH 6.6.
Purity≥95% by SDS-PAGE
Storage Avoid freeze/thaw
≤ -70°C
Do Not Freeze Ok to freeze
Special InstructionsFollowing initial thaw, aliquot and freeze (-70°C).
Toxicity Standard Handling
ReferencesVaughan, D.E., et al. 1995. J. Clin. Invest. 95, 995.
Dimitri, G., et al. 1993. Boll. Chim. Farmaceutico 132, 272.
Janicke, F., et al. 1993. Breast Cancer Res. Treatment 24, 195.
Klasser, K.J., et al. 1993. Coron. Artery Dis. 4, 713.
Robbie, L.A., et al. 1993. Thromb. Hemost. 70, 307.
Lawrence, D., et al. 1989. Eur. J. Biochem. 186, 523.
Collen, D. and Lijnen, H.R. 1987. In The Molecular Basis of Blood Diseases (Stamatoyannopoulus, G., et al. Eds.) W.B. Saunders
Ginsberg, D., et al. 1986. J. Clin. Invest. 78, 1673.
Vassalli, J.D., et al. 1985. J. Cell Biol. 100, 86.